Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

Weskamm, Leonie M.; Fathi, Anahita; Raadsen, Matthijs P.; Mykytyn, Anna Z; Koch, Till; Spohn, Michael; Friedrich, Monika; Haagmans, Bart L.; Becker, Stephan; Sutter, Gerd; Dahlke, Christine; Addo, Marylyn M.; Bartels, Etienne; Gundlach, Swantje; Hesterkamp, Thomas; Krähling, Verena; Lassen, Susan; Ly, My L.; Pötsch, Joseph H.; Schmiedel, Stefan; Volz, Asisa; Zinser, Madeleine

doi:10.1016/j.xcrm.2022.100685

Cited by 13 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…313 The third dose of MVA-MERS-S boosted at 12 ± 4 months induced persistent MERS-CoV-S-specific B cells and antibodies for 2 years after the latest boost. 314 MVA-SARS-CoV-2-S was constructed by expressing the fulllength SARS-CoV-2 S protein based on the MVA vector. After two doses of vaccination, binding IgG antibodies and NAbs against SARS-CoV-2 were induced in mice, golden hamsters and rhesus macaques.…”

Section: Other Poxvirus Vectored Vaccines In Clinical: Mva-based Cchf...mentioning

confidence: 99%

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Wang

Liang

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

Human diseases, particularly infectious diseases and cancers, pose unprecedented challenges to public health security and the global economy. The development and distribution of novel prophylactic and therapeutic vaccines are the prioritized countermeasures of human disease. Among all vaccine platforms, viral vector vaccines offer distinguished advantages and represent prominent choices for pathogens that have hampered control efforts based on conventional vaccine approaches. Currently, viral vector vaccines remain one of the best strategies for induction of robust humoral and cellular immunity against human diseases. Numerous viruses of different families and origins, including vesicular stomatitis virus, rabies virus, parainfluenza virus, measles virus, Newcastle disease virus, influenza virus, adenovirus and poxvirus, are deemed to be prominent viral vectors that differ in structural characteristics, design strategy, antigen presentation capability, immunogenicity and protective efficacy. This review summarized the overall profile of the design strategies, progress in advance and steps taken to address barriers to the deployment of these viral vector vaccines, simultaneously highlighting their potential for mucosal delivery, therapeutic application in cancer as well as other key aspects concerning the rational application of these viral vector vaccines. Appropriate and accurate technological advances in viral vector vaccines would consolidate their position as a leading approach to accelerate breakthroughs in novel vaccines and facilitate a rapid response to public health emergencies.

show abstract

Section: Other Poxvirus Vectored Vaccines In Clinical: Mva-based Cchf...mentioning

confidence: 99%

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Wang

Liang

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…151 Thus, no specific vaccine or treatment against MERS-CoV is currently available, although several products are under development. 152 Different studies have reported the preclinical 153 and clinical 154 , 155 evaluation of MVA-based vaccine candidates targeting the MERS-CoV spike (S) glycoprotein. In animal models (mice and camels) MVA-MERS-S induced high levels of NAbs with capacity to reduce the transmission of the virus to humans.…”

Section: Mva and Nyvac Poxvirus Strains As Vaccine Candidates Against...mentioning

confidence: 99%

“… 153 The vector was also evaluated as prophylactic vaccine in clinical trials ( Table 4 ), demonstrating safety and tolerability profiles and eliciting specific long-term antibodies and B cell immunity. 154 , 155 …”

Section: Mva and Nyvac Poxvirus Strains As Vaccine Candidates Against...mentioning

confidence: 99%

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

Perdiguero

Pérez

Marcos-Villar

et al. 2023

Journal of Molecular Biology

View full text Add to dashboard Cite

“…Although efforts to develop MERS-CoV vaccines have been undertaken, most of the vaccine trials remain in the preclinical or clinical stage and the vaccines have therefore not been approved for human use [7] , [8] . The MVA-MERS-S, GLS-5300 DNA, and ChAdOx1 vaccines are three MERS-CoV vaccines that have undergone phase 1 trials [9] , [10] , [11] . Understanding the safety and immunogenicity of the current vaccines is important for the fast-tracking of the development of effective vaccines that could stave off a future outbreak of disease.…”

Section: Introductionmentioning

confidence: 99%

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines

Kandeel

Morsy

El‐Lateef

et al. 2023

International Immunopharmacology

View full text Add to dashboard Cite

Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine

Cited by 13 publications

References 50 publications

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases

Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines

Contact Info

Product

Resources

About